CA3242855A1 - Treatments based on the granulocyte and macrophage colony stimulation factor against neurodegenerative or neurological diseases or disorders - Google Patents

Treatments based on the granulocyte and macrophage colony stimulation factor against neurodegenerative or neurological diseases or disorders

Info

Publication number
CA3242855A1
CA3242855A1 CA3242855A CA3242855A CA3242855A1 CA 3242855 A1 CA3242855 A1 CA 3242855A1 CA 3242855 A CA3242855 A CA 3242855A CA 3242855 A CA3242855 A CA 3242855A CA 3242855 A1 CA3242855 A1 CA 3242855A1
Authority
CA
Canada
Prior art keywords
granulocyte
neurodegenerative
disorders
stimulating factor
macrophage colony
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242855A
Other languages
English (en)
French (fr)
Inventor
Edwin Rock
Ila Joshi
Timothy Boyd
Original Assignee
Partner Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Partner Therapeutics Inc filed Critical Partner Therapeutics Inc
Publication of CA3242855A1 publication Critical patent/CA3242855A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3242855A 2022-02-11 2023-02-10 Treatments based on the granulocyte and macrophage colony stimulation factor against neurodegenerative or neurological diseases or disorders Pending CA3242855A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309220P 2022-02-11 2022-02-11
US63/309,220 2022-02-11
PCT/US2023/062374 WO2023154855A2 (en) 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Publications (1)

Publication Number Publication Date
CA3242855A1 true CA3242855A1 (en) 2023-08-17

Family

ID=87565120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242855A Pending CA3242855A1 (en) 2022-02-11 2023-02-10 Treatments based on the granulocyte and macrophage colony stimulation factor against neurodegenerative or neurological diseases or disorders

Country Status (8)

Country Link
US (1) US20250134959A1 (https=)
EP (1) EP4475874A2 (https=)
JP (1) JP2025508308A (https=)
KR (1) KR20240147980A (https=)
CN (1) CN118660715A (https=)
AU (1) AU2023219770A1 (https=)
CA (1) CA3242855A1 (https=)
WO (1) WO2023154855A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235795A2 (en) * 2022-06-01 2023-12-07 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
WO2025168003A1 (zh) * 2024-02-06 2025-08-14 上海市第四人民医院 一种治疗神经退行性疾病的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
JP2023514972A (ja) * 2020-02-12 2023-04-12 ザ スクリプス リサーチ インスティテュート 長時間作用型ｇｍ－ｃｓｆおよび使用方法

Also Published As

Publication number Publication date
CN118660715A (zh) 2024-09-17
WO2023154855A2 (en) 2023-08-17
KR20240147980A (ko) 2024-10-10
EP4475874A2 (en) 2024-12-18
JP2025508308A (ja) 2025-03-26
AU2023219770A1 (en) 2024-08-22
WO2023154855A3 (en) 2023-10-05
US20250134959A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
CA3242855A1 (en) Treatments based on the granulocyte and macrophage colony stimulation factor against neurodegenerative or neurological diseases or disorders
WO2021163346A3 (en) Long-acting gm-csf and methods of use
AU2024211867A1 (en) 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
AU2022298746A1 (en) Beta-lactam derivatives for the treatment of diseases
EP4125947A4 (en) NOVEL ANUCLATED CELLS FOR THE TREATMENT OF DISEASES
AU2024216821A1 (en) Rifabutin analogs for the treatment of bacterial diseases
CA3264922A1 (en) METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGPTL3
EP4217355A4 (en) AGENTS FOR TREATING DISEASES BY INHIBITING FOXO1
WO2024086692A3 (en) Herpesvirus-induced gene or protein expression and methods for treating neurological disorders
WO2023138433A3 (zh) 具有ripk1抑制活性的酰胺化合物、其制备方法及其用途
CA3300058A1 (en) Treatment of neurological diseases
AU2024902833A0 (en) Treatment of diseases associated with mitophagy
CA3279062A1 (en) 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
CA3278922A1 (en) Rifabutin analogs for the treatment of bacterial diseases
HK40109636A (en) Methods of treating neurological diseases
CA3297910A1 (en) Therapeutic use of fibroblasts for the treatment of psoriasis
HK40102829A (en) Treatment of cns diseases with sgc stimulators
CA3279118A1 (en) Methods of treating neurodegenerative diseases or conditions
HK40123266A (en) Methods for the treatment of neurodegenerative disorders
AU2024396398A1 (en) Therapy for the treatment of multiple myeloma
EP4153182A4 (en) TREATMENT OF ADAPTATION DISORDERS
CA3275571A1 (en) Methods of treating neurological disorders
HK40131589A (zh) 使用sgc刺激剂治疗线粒体疾病
CA3296082A1 (fr) Composition pour le traitement de désordres inflammatoires cutanés
CA3272977A1 (en) Methods of treating or preventing liver diseases or disorders

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240702

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240702

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR PRIORITY RECEIVED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: FIRST IPC ASSIGNED

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W270 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: SEQUENCE LISTING - RECEIVED

Effective date: 20240703

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W270 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: SEQUENCE LISTING - RECEIVED

Effective date: 20240703

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250127

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260202